IN8BIO, INC. (INAB) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Company: IN8BIO, INC.
Reporting Period: Quarter ended June 30, 2025 (Q2 2025)
Business Model: Clinical-stage biopharmaceutical company focused on gamma-delta T cell product candidates for cancer and autoimmune diseases. The company has no approved products and has not generated product revenue.
Key Corporate Action: A 1-for-30 reverse stock split was effected on June 5, 2025. All share and per-share data in this filing have been restated to reflect this split.
Key Financial Metrics
| Metric (in thousands, except per share) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(5,094) | $(8,629) | $(10,644) | $(17,191) |
| Net Loss Per Share (Basic & Diluted) | $(1.24) | $(5.51) | $(3.65) | $(11.59) |
| Cash and Restricted Cash | $13,497 | $10,476 | $13,497 | $10,476 |
| Accumulated Deficit | $(132,300) | $(108,410) | $(132,300) | $(108,410) |
| Operating Cash Flow (YTD) | $(7,049) | $(14,010) | $(7,049) | $(14,010) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 40% in Q2 2025 ($5.2M) compared to Q2 2024 ($8.7M). This was driven by a 52% reduction in R&D expenses and a 23% reduction in G&A expenses, primarily due to headcount reductions and lower clinical trial costs.
- Capital Raising: The company raised approximately $7.4 million in net proceeds from its At-The-Market (ATM) program and $1.9 million from warrant exercises/exchanges during the six months ended June 30, 2025.
- Balance Sheet: Cash balances increased from $11.1 million at year-end 2024 to $13.2 million at June 30, 2025, despite ongoing operational losses, due to financing activities.
- Stock Structure: The 1-for-30 reverse stock split significantly reduced the number of outstanding shares and adjusted per-share metrics retroactively.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern. As of June 30, 2025, cash of $13.2 million is projected to fund operations only into June 2026.
- Liquidity Strategy: The company is pursuing additional capital through equity/debt offerings (including ATM), strategic collaborations, and licensing. Potential proceeds from outstanding warrants (Series A, B, and C) could total up to $13.9 million if fully exercised, though there is no assurance this will occur.
- Operational Prioritization: In September 2024, the company suspended enrollment in the INB-400 Phase 2 trial to conserve cash. It is focusing on advancing INB-100 (AML) and exploring partnerships for other assets.
- Clinical Highlights:
- INB-100: 100% of AML patients in the Phase 1 trial remain in complete remission with 100% progression-free survival at one year post-transplant.
- INB-200: Data presented at ASCO 2025 showed median progression-free survival of 16.1 months for GBM patients receiving repeated doses, more than double the standard of care.
- INB-600: New preclinical data demonstrated efficacy in depleting B cells in lupus samples with minimal inflammatory cytokine release.
- Risks: Risks include failure to raise additional capital, potential dilution from future financing, clinical trial failures, regulatory hurdles, and dependence on third-party manufacturers.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash exhaustion (projected June 2026) and the status of any new financing agreements.
- Warrant Exercise Probability: Assess the likelihood of Series A, B, and C warrant holders exercising their options to provide the projected $13.9M in proceeds.
- INB-400 Status: Confirm if the suspension of the INB-400 Phase 2 trial is permanent or if a partnership has been secured to resume it.
- Reverse Split Impact: Monitor post-split trading liquidity and compliance with Nasdaq listing requirements.
- Going Concern Audit: Review the independent auditor's report for the upcoming 10-K to see if the "substantial doubt" qualification persists.